08:39 AM EDT, 08/02/2024 (MT Newswires) -- ArcBest ( ARCB ) reported Q2 non-GAAP net income Friday of $1.98 per diluted share, up from $1.54 a year earlier. Analysts polled by Capital IQ expected $2.06. Revenue for the quarter ended June 30 was $1.08 billion, down from $1.10 billion a year earlier. Analysts surveyed by Capital IQ expected $1.06 billion....

08:36 AM EDT, 08/02/2024 (MT Newswires) -- Twist Bioscience ( TWST ) reported a fiscal Q3 loss Friday of $1.47 per diluted share, widening from a loss of $1.01 a year earlier. Analysts polled by Capital IQ expected a per-share loss of $0.77. Revenue for the quarter ended June 30 was $81.5 million, up from $63.7 million a year earlier....

08:42 AM EDT, 08/02/2024 (MT Newswires) -- Integrated Electrical Services (IESC) reported fiscal Q3 adjusted earnings Friday of $2.67 per diluted share, up from $1.08 a year earlier. Revenue for the quarter ended June 30 was $768.4 million, up from $584.4 million a year earlier. Analysts' estimates were not readily available for comparison. The company also said its board has...

Thursday, the FDA approved Adaptimmune Therapeutics ( ADAP ) plc’s Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma, a rare type of cancer that tends to occur near large joints, mainly the knees. The approval covers patients who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen. This indication is approved under...